Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Barclays PLC grew its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 101.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 342,973 shares of the company’s stock after acquiring an additional 172,745 shares during the quarter. Barclays PLC owned about 0.16% of Allogene Therapeutics worth $959,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ALLO. Geode Capital Management LLC raised its position in Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after purchasing an additional 407,070 shares during the period. MML Investors Services LLC purchased a new stake in shares of Allogene Therapeutics in the third quarter worth approximately $56,000. Zacks Investment Management purchased a new position in Allogene Therapeutics during the 3rd quarter valued at $1,446,000. EP Wealth Advisors LLC grew its position in Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock valued at $69,000 after acquiring an additional 13,625 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Allogene Therapeutics in the third quarter worth $91,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Stock Performance

NASDAQ ALLO opened at $1.92 on Wednesday. The company has a market cap of $402.57 million, a PE ratio of -1.23 and a beta of 0.86. The firm’s 50 day moving average price is $2.30 and its 200-day moving average price is $2.53. Allogene Therapeutics, Inc. has a 52-week low of $1.78 and a 52-week high of $5.78.

Wall Street Analyst Weigh In

ALLO has been the subject of a number of recent analyst reports. Piper Sandler lowered their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research report on Friday, November 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).